Silence Therapeutics reports Q2 2026 financial results, R&D expense decrease to $9.1M
The company reported cash and equivalents of $72.1 million and a decrease in R&D expenses for Q2 2026, driven by completion of zerlasiran Phase 3 readiness and reduced personnel costs.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day